PVLA

Palvella Therapeutics Inc

Add to Watchlist

Advanced Chart

37.440

-1.44(-3.704%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

39.200

Open

39.200

VWAP

37.83

Vol

260.17K

Mkt Cap

413.92M

Low

36.845

Amount

9.84M

EV/EBITDA(TTM)

Total Shares

11.06M

354.22M

EV/OCF(TTM)

P/S(TTM)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

6 Analyst Rating

24.20% Upside

Wall Street analysts forecast PVLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PVLA is 46.50 USD with a low forecast of 38.00 USD and a high forecast of 52.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

24.20% Upside

Current: 37.440

Low

38.00

Averages

46.50

High

52.00

24.20% Upside

Current: 37.440

Low

38.00

Averages

46.50

High

52.00

Truist

Danielle Brill

Buy

initiated

$56

2025-07-21

Reason

Truist

Danielle Brill

Price Target

$56

2025-07-21

initiated

Buy

Reason

Truist analyst Danielle Brill initiated coverage of Palvella Therapeutics with a Buy rating and $56 price target. Palvella is in a sweet spot for biotech investment with QTORIN, a de-risked potential pipeline in a product with clean proof-of-concept data in microcystic lymphatic malformations, a rare genetic skin disease, a registrational trial that has been optimized to replicate Phase 2 findings, and a potential blockbuster opportunity with no marketed competition, the analyst tells investors in a research note. The firm sees a value inflection approaching in the next 5-9 months.

Canaccord

Whitney Ijem

Buy

downgrade

$53 -> $52

2025-05-16

Reason

Canaccord

Whitney Ijem

Price Target

$53 -> $52

2025-05-16

downgrade

Buy

Reason

Canaccord analyst Whitney Ijem lowered the firm's price target on Palvella Therapeutics to $52 from $53 and keeps a Buy rating on the shares. The firm said its 1Q25 earnings report was incrementally positive relative to our recent initiation. Pipeline progress remains on track, and newly announced was that QTORIN rapamycin's Ph3 had exceeded the target enrollment goal of n=40 ahead of schedule.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Palvella Therapeutics Inc (PVLA.O) is -13.62, compared to its 5-year average forward P/E of -7.32. For a more detailed relative valuation and DCF analysis to assess Palvella Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.32

Current PE

-13.62

Overvalued PE

-5.12

Undervalued PE

-9.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.65

Current EV/EBITDA

-10.11

Overvalued EV/EBITDA

-0.93

Undervalued EV/EBITDA

-8.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

+347.47%

-7.87M

Operating Profit

FY2025Q1

YoY :

+222.75%

-8.19M

Net Income after Tax

FY2025Q1

YoY :

-51.95%

-0.74

EPS - Diluted

FY2025Q1

N/A

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

36.1K

Volume

Months

6-9

2.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

PVLA News & Events

Events Timeline

2025-06-30 (ET)

2025-06-30

07:34:38

Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes

2025-06-23 (ET)

2025-06-23

07:45:59

Palvella Therapeutics completes enrollment in Phase 3 SELVA trial

2025-06-18 (ET)

2025-06-18

07:34:36

Palvella Therapeutics granted sixth U.S. patent covering rapamycin

News

2.0

06-30Newsfilter

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

9.0

06-18NASDAQ.COM

Palvella Therapeutics Secures Patent for QTORIN™ Rapamycin, Strengthening Intellectual Property Strategy Through 2038

9.0

06-18Newsfilter

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

People Also Watch

FAQ

What is Palvella Therapeutics Inc (PVLA) stock price today?

The current price of PVLA is 37.44 USD — it has decreased -3.7 % in the last trading day.

PVLA

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PVLA News & Events

Events Timeline

News

People Also Watch

FAQ

What is Palvella Therapeutics Inc (PVLA) stock price today?

What is Palvella Therapeutics Inc (PVLA)'s business?

What is the price predicton of PVLA Stock?

What is Palvella Therapeutics Inc (PVLA)'s revenue for the last quarter?

What is Palvella Therapeutics Inc (PVLA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Palvella Therapeutics Inc (PVLA)'s fundamentals?

How many employees does Palvella Therapeutics Inc (PVLA). have?

What is Palvella Therapeutics Inc (PVLA) market cap?